Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 12/20 | 0.61 |
| ▸ | JAK2 | O60674 | 2/20 | 0.50 |
| ▸ | JAK3 | P52333 | 2/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.45 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7014868 | 0.86 | LCK (0.69) | LCKJAK2JAK3AURKAAURKB | |
| SCHEMBL7105538 | 0.83 | LCK (0.60) | LCKJAK2JAK3AURKAAURKB | |
| SCHEMBL7105532 | 0.83 | LCK (0.60) | LCKJAK2JAK3AURKAAURKB | |
| SCHEMBL7021779 | 0.82 | LCK (0.70) | LCKJAK2JAK3AURKAAURKB | |
| SCHEMBL7021040 | 0.82 | LCK (0.64) | LCKJAK2JAK3AURKAAURKB | |
| SCHEMBL7018308 | 0.82 | LCK (0.64) | LCKJAK2JAK3AURKAAURKB | |
| SCHEMBL7023496 | 0.81 | LCK (0.62) | LCKJAK2JAK3AURKAAURKB | |
| SCHEMBL7018072 | 0.81 | LCK (0.62) | LCKJAK2JAK3AURKAAURKB | |
| SCHEMBL7024433 | 0.81 | LCK (0.62) | LCKJAK2JAK3AURKAAURKB | |
| SCHEMBL7015030 | 0.81 | LCK (0.71) | LCKJAK2JAK3AURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1206265-B1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO INC (US) | 2003-11-12 | — | — | EP | disclosed |
| US-6498165-B1 | PYRIMIDINE COMPOUNDS; PROPHYLAXIS AND TREATMENT OF SUCH AS IMMUNE DISEASES, HYPERPROLIFERATIVE DISORDERS, CANCER, ANGIOGENSIS, ATHEROSCELEROSIS, GRAFT REJECTION, RHEUMATOID ARTHRITIS, PSORIASIS | MERCK & CO., INC. | 2002-12-24 | — | — | US | disclosed |